KR101446166B1 - 비 호모안드로스테인 및 비 헤테로안드로스테인의 아미노 유도체 - Google Patents

비 호모안드로스테인 및 비 헤테로안드로스테인의 아미노 유도체 Download PDF

Info

Publication number
KR101446166B1
KR101446166B1 KR1020097001487A KR20097001487A KR101446166B1 KR 101446166 B1 KR101446166 B1 KR 101446166B1 KR 1020097001487 A KR1020097001487 A KR 1020097001487A KR 20097001487 A KR20097001487 A KR 20097001487A KR 101446166 B1 KR101446166 B1 KR 101446166B1
Authority
KR
South Korea
Prior art keywords
homoandrostane
aza
hydrochloride
aminoethoxyimino
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097001487A
Other languages
English (en)
Korean (ko)
Other versions
KR20090023730A (ko
Inventor
알베르토 세리
바바라 모로
마코 토리
지울리오 카르자나
지우세페 바앙치
마라 페란디
파트리지아 페라리
마리아 피아 자파비그나
레오나르도 반피
지우세페 지아칼로네
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20090023730A publication Critical patent/KR20090023730A/ko
Application granted granted Critical
Publication of KR101446166B1 publication Critical patent/KR101446166B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/004—Expansion of ring B by one atom, e.g. B homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020097001487A 2006-06-23 2007-05-31 비 호모안드로스테인 및 비 헤테로안드로스테인의 아미노 유도체 Expired - Fee Related KR101446166B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06116001 2006-06-23
EP06116001.6 2006-06-23
PCT/EP2007/055366 WO2007147713A1 (en) 2006-06-23 2007-05-31 Amino derivatives of b-homoandrostanes and b-heteroandrostanes

Publications (2)

Publication Number Publication Date
KR20090023730A KR20090023730A (ko) 2009-03-05
KR101446166B1 true KR101446166B1 (ko) 2014-10-01

Family

ID=37603055

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001487A Expired - Fee Related KR101446166B1 (ko) 2006-06-23 2007-05-31 비 호모안드로스테인 및 비 헤테로안드로스테인의 아미노 유도체

Country Status (20)

Country Link
US (1) US8022203B2 (https=)
EP (1) EP2032593B1 (https=)
JP (1) JP4664433B2 (https=)
KR (1) KR101446166B1 (https=)
CN (1) CN101479291B (https=)
AR (1) AR061561A1 (https=)
AT (1) ATE497504T1 (https=)
AU (1) AU2007263117B2 (https=)
BR (1) BRPI0713439A2 (https=)
CA (1) CA2654354C (https=)
CY (1) CY1112012T1 (https=)
DE (1) DE602007012348D1 (https=)
DK (1) DK2032593T3 (https=)
EA (1) EA014333B1 (https=)
ES (1) ES2359544T3 (https=)
MX (1) MX2008016425A (https=)
PL (1) PL2032593T3 (https=)
SI (1) SI2032593T1 (https=)
TW (1) TWI372762B (https=)
WO (1) WO2007147713A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2422603T3 (es) 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
JP5450387B2 (ja) * 2008-04-02 2014-03-26 株式会社カネカ （ｓ）−３−（１−シアノ−１，１−ジフェニルメチル）−ピロリジンの製造法
US8518934B2 (en) 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
HUE027408T2 (en) * 2009-03-23 2016-10-28 Sigma Tau Ind Farmaceuti Proteinuria, 5ß, 14β-androstane derivatives for the treatment of glomerulosclerosis and renal failure
GB201104199D0 (en) 2011-03-11 2011-04-27 Syngenta Participations Ag Plant growth regulator compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825197A2 (en) * 1996-08-19 1998-02-25 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2806029A (en) * 1956-07-16 1957-09-10 Searle & Co 3-oxygenated 12a-aza-c-homopregnane-12, 20-diones and congeners
US3136584A (en) * 1963-01-25 1964-06-09 Whitlock Associates Inc Bulk material hopper unloader
US3328408A (en) * 1964-01-30 1967-06-27 Smith 6-azaestranes, intermediates and process
WO2003015715A2 (en) * 2001-08-20 2003-02-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as antithrombotic agents
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2006002381A1 (en) * 2004-06-24 2006-01-05 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825197A2 (en) * 1996-08-19 1998-02-25 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Med Chem 19(5): 719-721 (1976. 5.) *
J Med Chem 46: 3644-3654(2003) *

Also Published As

Publication number Publication date
KR20090023730A (ko) 2009-03-05
DE602007012348D1 (de) 2011-03-17
ES2359544T3 (es) 2011-05-24
US20090209506A1 (en) 2009-08-20
CN101479291A (zh) 2009-07-08
TW200817427A (en) 2008-04-16
JP2009541410A (ja) 2009-11-26
EA014333B1 (ru) 2010-10-29
WO2007147713A1 (en) 2007-12-27
ATE497504T1 (de) 2011-02-15
AR061561A1 (es) 2008-09-03
HK1134097A1 (en) 2010-04-16
CY1112012T1 (el) 2015-11-04
US8022203B2 (en) 2011-09-20
CA2654354A1 (en) 2007-12-27
AU2007263117A1 (en) 2007-12-27
SI2032593T1 (sl) 2011-05-31
BRPI0713439A2 (pt) 2012-03-06
MX2008016425A (es) 2009-01-21
TWI372762B (en) 2012-09-21
AU2007263117A2 (en) 2009-03-12
DK2032593T3 (da) 2011-05-16
CA2654354C (en) 2014-12-23
EA200970046A1 (ru) 2009-06-30
PL2032593T3 (pl) 2011-05-31
JP4664433B2 (ja) 2011-04-06
EP2032593B1 (en) 2011-02-02
CN101479291B (zh) 2012-09-19
EP2032593A1 (en) 2009-03-11
AU2007263117B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
ES2403366T3 (es) Derivados azaheterociclilo de androstanos y androstenos como medicamentos para transtornos cardiovasculares
CA2649175C (en) Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
CN105518015B (zh) 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
KR101446166B1 (ko) 비 호모안드로스테인 및 비 헤테로안드로스테인의 아미노 유도체
EP3013845A1 (en) Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1
KR101585275B1 (ko) 심혈관 질환용 약제로서의 2 치환 및/또는 4 치환 안드로스탄 및 안드로스텐의 아미노옥심 유도체
HK1134097B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170925

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170925